Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

However, guidelines already recommend that antithrombotics after TAVR consist of lifelong SAPT (aspirin 75-100 mg daily or ...

Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced ...

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced ...

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

Society for Cardiovascular Angiography & Interventions (SCAI) meeting, SCAI Scientific Sessions 2025, will kick off on ...

This technique entails percutaneous delivery of a bioprosthetic valve ... The search parameters were as follows: TI (Title) = (“Transcatheter Aortic Valve Replacement” OR “transcatheter aortic valve ...